Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes
References (36)
- et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: A randomized prospective 6-year study
Diabetes Res Clin Pract
(1995) - et al.
Therapy in type 2 diabetes: Insulin glargine vs. NPH insulin both in combination with glimepiride
Arch Med Res
(2006) - et al.
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mel litus using a basal-bolus regimen
Clin Ther
(2004) - et al.
Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes [published correction appears in Diabetes Res Clin Pract. 2006;72:112]
Diabetes Res Clin Pract
(2004) - et al.
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy [published correction appears in Clin Ther. 2005;27: 1112]
Clin Ther
(2004) - et al.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
BMJ
(2000) - et al.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
N Engl J Med
(2003) Clinical Guidelines Task Force. Global guideline for type 2 diabetes
(2005)When oral agents fail: Practical barriers to starting insulin
Int J Obes Relat Metab Disord
(2002)Overcoming obstacles: New management options
Eur J Endocrinol
(2004)
The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care
(2003)
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Diabetes Care
(2006)
Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with type 2 diabetes
Norm Metab Res
(2003)
The mechanism of protraction of insulin detemir, a long- acting, acylated analog of human insulin
Pharm Res
(2004)
Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients
Diabet Med
(2003)
A one year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes
Horm Metab Res
(2003)
Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
Diabetes Care
(2003)
The 1 2-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes
Diabetes Technol Ther
(2004)
Cited by (266)
Insulin therapy in older people with type 2 diabetes mellitus: The lighting of the Gerodiab study
2022, Bulletin de l'Academie Nationale de MedecineExploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir
2020, European Journal of Pharmaceutics and BiopharmaceuticsExploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification
2017, Diabetes Research and Clinical Practice
Copyright © 2006 Published by Elsevier Inc.